#1 Clinical Trials Search in Europe

Study on the Safety and Effectiveness of Rilzabrutinib for Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

1 1

What is this study about?

This clinical trial is focused on studying a condition known as Immune Thrombocytopenia (ITP), which is a disorder that can lead to easy or excessive bruising and bleeding due to low levels of platelets in the blood. The trial is testing a medication called Rilzabrutinib, also known by its code name PRN1008. This medication is taken orally in the form of a tablet. The purpose of the study is to evaluate the effectiveness and safety of Rilzabrutinib in treating adults and adolescents who have persistent or chronic ITP.

Participants in the study will be randomly assigned to receive either Rilzabrutinib or a placebo, which looks like the real medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the initial phase. The study will last for a total of 24 weeks, with an additional open-label extension where all participants may receive Rilzabrutinib. The main goal is to see if Rilzabrutinib can help maintain a stable platelet count without the need for additional rescue treatments.

Throughout the study, participants will have regular check-ups to monitor their platelet levels and overall health. The trial aims to provide valuable information on how well Rilzabrutinib works in managing ITP and its safety profile. This research could potentially lead to new treatment options for those living with this condition.

1 initial treatment phase

The trial begins with a 24-week period where you will receive either the study medication, rilzabrutinib, or a placebo. The placebo looks like the study medication but does not contain the active ingredient.

You will take the medication orally in the form of a tablet. The dosage is 400 mg, and it is taken as directed by the study team.

2 monitoring and assessment

Throughout the 24-week period, your platelet levels will be regularly monitored. The goal is to achieve a platelet count of at least 50,000 per microliter for at least 8 out of the last 12 weeks without needing additional treatment.

Your health will be assessed through various tests to ensure the safety and effectiveness of the treatment. This includes monitoring for any side effects or changes in your condition.

3 open-label extension

After the initial 24-week period, there is an option to enter an open-label extension phase. In this phase, all participants will receive rilzabrutinib regardless of their initial group assignment.

This phase allows for continued monitoring and assessment of the medication’s long-term effects and safety.

4 final evaluation

At the end of the study, a final evaluation will be conducted to assess the overall effectiveness and safety of the treatment.

This includes a comprehensive review of your health status, platelet counts, and any side effects experienced during the trial.

Who Can Join the Study?

  • Patients must have primary Immune Thrombocytopenia (ITP) for more than 6 months if they are aged 12 to under 18 years, or more than 3 months if they are 18 years or older.
  • Patients should have previously responded to treatments like IVIg/anti-D or corticosteroids (CSs), but the response did not last. They must also have issues with standard ITP treatments, such as intolerance, insufficient response, or contraindications.
  • During the screening period, patients must have an average of two platelet counts taken at least 5 days apart that are less than 30,000 per microliter, and no single count should be more than 35,000 per microliter. Pediatric patients must also need treatment for ITP as assessed by the doctor.
  • Patients must have adequate blood, liver, and kidney function. This includes a certain level of neutrophils (a type of white blood cell), AST/ALT (liver enzymes), albumin (a protein in the blood), and bilirubin (a substance made by the liver). The glomerular filtration rate (a measure of kidney function) must be above 50.
  • Patients must have a hemoglobin level greater than 9 grams per deciliter within one week before starting the study. Hemoglobin is a protein in red blood cells that carries oxygen.
  • All patients must use contraception according to local regulations if they are participating in the study.
  • Patients must be able to provide written informed consent or assent, and if they are minors, consent must also be obtained from their guardian. They must agree to follow the study’s schedule of assessments.

Who Cannot Join the Study?

  • Patients who have a different condition than Immune Thrombocytopenia (ITP) cannot participate. ITP is a condition where the body has a low number of platelets, which are cells that help the blood to clot.
  • Patients who are not within the specified age range cannot participate. The age range includes children, teenagers, and adults.
  • Patients who are not willing to avoid using other treatments that could interfere with the study cannot participate. This means they should not use any other treatment that could affect their platelet count during the study.
  • Patients who are not able to follow the study procedures or attend the required visits cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have any other medical condition that the study doctors think might make it unsafe for them to participate cannot join the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hospital General Universitario Gregorio Maranon Madrid Spain
Wojewodzki Szpital Specjalistyczny Im. Janusza Korczaka W Slupsku Sp. z o.o. Slupsk Poland
Azienda Sanitaria Universitaria Giuliano Isontina Trieste Italy
Hospital Clinico Universitario De Valencia Valencia Spain
Virgen del Rocío University Hospital Sevilla Spain
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Semmelweis University Budapest Hungary
Robert Debre University Hospital Paris France
Sykehuset Oestfold HF Kalnes Graalum Norway
Centre Hospitalier Universitaire Amiens Picardie Amiens France
Area De Salud De Burgos Y Soria Burgos Spain
Hospital Universitario Virgen De La Victoria Malaga Spain
Golobluwtkmjafadd Vpkutlurr Pwev Apkskx Eblrtsqm Ocvcom Krdvfb Gyor Hungary
Axglnmx Unzig Szawehidw Llqdha Ds Bimxbzi Bologna Italy
Hzeutkvt Di Lq Sjebx Cpti I Svvm Ptm Barcelona Spain
Fvuosxmbm Pteb Le Ivuwlvzivozhs Byxtbvrkr Duw Hbtzesac Uafzpzseulbuv Lb Pex Madrid Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not recruiting
16.04.2021
Germany Germany
Not recruiting
16.04.2021
Hungary Hungary
Not recruiting
16.04.2021
Italy Italy
Not recruiting
16.04.2021
Norway Norway
Not recruiting
16.04.2021
Poland Poland
Not recruiting
16.04.2021
Spain Spain
Not recruiting
16.04.2021

Trial locations

Investigated drugs:

Rilzabrutinib (PRN1008) is an oral medication being studied for its effectiveness and safety in treating adults and adolescents with persistent or chronic immune thrombocytopenia (ITP). The trial aims to see how well this medication can help maintain a stable platelet count in patients who have not responded well to other treatments.

Immune Thrombocytopenia (ITP) – Immune Thrombocytopenia is a disorder characterized by a low platelet count, which can lead to easy or excessive bruising and bleeding. The condition occurs when the immune system mistakenly attacks and destroys platelets, which are essential for normal blood clotting. ITP can be acute, often resolving within six months, or chronic, lasting longer and requiring ongoing management. Symptoms may include petechiae, which are small red or purple spots on the skin, nosebleeds, and bleeding gums. The severity of bleeding varies among individuals, and some may experience no symptoms at all. The progression of ITP can be unpredictable, with periods of remission and relapse.

Trial ID:
2023-509401-71-00
Protocol code:
EFC17093
NCT ID:
NCT04562766
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A Study to Test How Safe Budoprutug Is and How Well It Works in Patients with Immune Thrombocytopenia

    Recruiting

    1 1
    Bulgaria Greece Spain

  • A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

    Recruiting

    1 1 1
    Bulgaria Croatia Czechia France Germany Greece +6